Singapore-based Esco Ventures has announced the launch of Carmine Therapeutics and execution of an exclusive license agreement for the technology developed in the laboratories of Professors Minh Le and Jiahai Shi at the City University of Hong Kong. 29 August 2019
Mustang Bio and St Jude Children’s Research Hospital have announced that MB-107, a lentiviral gene therapy for the treatment of X-linked severe combined immunodeficiency, also known as bubble boy disease, has been granted the Regenerative Medicine Advanced Therapy (RMAT) designation by the US Food and Drug Administration. 23 August 2019
Although some US Food and Drug Administration Priority Review Vouchers (PRVs) have changed hands for over $300 million, AstraZeneca looks like it’s getting a bargain, agreeing to pay just $95 million for one from Nordic biotech firm Swedish Orphan Biovitrum (Sobi). 22 August 2019
Cambridge, USA-based Oncorus has raised $79.5 million in a series B financing round. The oncolytic virus specialist received money from Cowen Healthcare Investments and Perceptive Advisors, among others. 22 August 2019
In the week that Vanda Pharmaceuticals’ hopes of adding a new indication for its sleep-wake disorder drug Hetlioz (tasimelteon) suffered a setback, the company has announced a couple of senior appointments. 21 August 2019
English patients with severe congenital hemophilia A without factor VIII inhibitors will receive Hemlibra (emicizumab) on the National Health Service (NHS). 21 August 2019
USA-based Bellicum Pharmaceuticals, a company focused on developing controllable cellular immunotherapies for cancers and orphan inherited blood disorders, is set to close a share offering on Wednesday. 21 August 2019
Analysis of the US Food and Drug Administration’s Orange Books, which among other information list drug patents as provided by pharmaceutical groups, shows no exclusivity for Gilead Sciences’ Truvada (emtricitabine/tenofovir) for preventive use, a treatment known as pre-exposure prophylaxis, or PrEP. 19 August 2019
Gilead Sciences and Galapagos have filed for European regulatory approval to market the JAK1 inhibitor filgotinib, for the treatment of adults with rheumatoid arthritis (RA). 16 August 2019
D&D Pharmatech, the parent company of Neuraly, Precision Molecular and Theraly Fibrosis, has raised $137.1 million a Series B financing backed by US and Korean investors. 15 August 2019
WuXi AppTec has said that over a tenth of its stock, worth up to $1.7 billion, will be sold by seven of its major shareholders in the next three months. 15 August 2019
California-based biotech Glycomine, focused on developing new therapies for rare diseases, says it has raised $33 million in a Series B financing led by Novo Holdings A/S. 8 August 2019
China-based drug developer I-Mab Biopharma has reportedly filed for an initial public offering (IPO) in the USA, which could raise up to $200 million. 5 August 2019
UK biotech Antikor Biopharma has entered into an investment agreement for up to $3.1 million with Hong Kong-based Essex Bio-Investment, a wholly-owned subsidiary of Essex Bio-Technology, which will enable Antikor to consolidate and expand its position as an innovator in fragment-drug conjugate (FDC) therapies for solid tumors. 5 August 2019
British RNA interference specialist Silence Therapeutics has appointed Jørgen Wittendorff as head of manufacturing, a newly-created role. He will be responsible for the process development and manufacturing. 5 August 2019
India has developed new guidelines aimed at safeguarding the development of gene therapies. The draft document, developed by the Indian Council of Medical Research, would prevent the use of gene editing in certain circumstances. 1 August 2019
Italian pharma major Recordati saw its shares rise more than 5% to 52.00 euros in early trading, as it announced a deal to expand its portfolio of marketed rare disease medicines. 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Bristol Myers Squibb has received a new approval from the US Food and Drug Administration for its blockbuster checkpoint blocker, Opdivo (nivolumab). 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
The US Food and Drug Administration (FDA) has granted the Gilead Sciences subsidiary Kite a Regenerative Medicine Advanced Therapy Designation (RMAT) for Yescarta (axicabtagene ciloleucel) for adults with newly-diagnosed, high-risk large B-cell lymphoma (LBCL). 3 October 2024
Kedrion Biopharma has finalized an agreement with Germany-based Biotest for the long-term commercialization and distribution of Yimmugo (immune globulin) in the USA. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Privately-held Ferring Pharmaceuticals has announced the opening of a global manufacturing hub in Finland for the drug substance of its intravesical non-replicating gene therapy Adstiladrin (nadofaragene firadenovec-vncg). 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
The BioIndustry Association (BIA), in collaboration with the Centre for Process Innovation (CPI), has published a new report on the UK’s mRNA sector. 2 October 2024
Aspen Neuroscience, a private biotechnology company specializing in autologous cell therapies, has announced the opening of a major new facility near its headquarters in San Diego. 2 October 2024
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024